<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">avk</journal-id><journal-title-group><journal-title xml:lang="ru">Архивъ внутренней медицины</journal-title><trans-title-group xml:lang="en"><trans-title>The Russian Archives of Internal Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2226-6704</issn><issn pub-type="epub">2411-6564</issn><publisher><publisher-name>“SINAPS” LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20514/2226-6704-2019-9-2-126-132</article-id><article-id custom-type="elpub" pub-id-type="custom">avk-903</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLE</subject></subj-group></article-categories><title-group><article-title>Молекулярные основы мышечного истощения: роль миостатина и протеинкиназы в β прогрессировании белковоэнергетической недостаточности у пациентов на гемодиализе</article-title><trans-title-group xml:lang="en"><trans-title>Molecular bases of muscular definition: the role of myostatin and proteinkinase β in progression of protein-energy waste in patients on hemodialysis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кузярова</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuzyarova</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра внутренних болезней № 2.</p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Internal Medicine Department № 2.</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">lina.kuzyarova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гасанов</surname><given-names>М. З.</given-names></name><name name-style="western" xml:lang="en"><surname>Gasanov</surname><given-names>M. Z.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра внутренних болезней № 1.</p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Internal Medicine Department №1.</p><p>Rostov-on-Don</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Батюшин</surname><given-names>М. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Batyushin</surname><given-names>M. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра внутренних болезней № 2.</p></bio><bio xml:lang="en"><p>Internal Medicine Department № 2.</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Голубева</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Golubeva</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Rostov-on-Don</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО Ростовский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Rostov State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Гемодиализный центр Ростов, ООО</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Hemodialysis Center Rostov, LLC</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>30</day><month>03</month><year>2019</year></pub-date><volume>9</volume><issue>2</issue><fpage>126</fpage><lpage>132</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кузярова А.С., Гасанов М.З., Батюшин М.М., Голубева О.В., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Кузярова А.С., Гасанов М.З., Батюшин М.М., Голубева О.В.</copyright-holder><copyright-holder xml:lang="en">Kuzyarova A.S., Gasanov M.Z., Batyushin M.M., Golubeva O.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.medarhive.ru/jour/article/view/903">https://www.medarhive.ru/jour/article/view/903</self-uri><abstract><p>Совершенствование нефрологической службы и повышение доступности гемодиализа создают предпосылки для более детального анализа осложнений и сопутствующих заболеваний, с ним ассоциированных. Одним из основных клинических состояний, значительно ухудшающих прогноз пациента, является белково-энергетическая недостаточность (БЭН), проявляющаяся потерей мышечной массы, силы и работоспособности скелетной мускулатуры, которая, в свою очередь, приводит к снижению качества жизни, а, нередко, к инвалидизации и смерти.</p><sec><title>Цель исследования</title><p>Цель исследования: оценка взаимосвязи миостатина и протеинкиназы β, как маркеров катаболического каскада, с проявлениями БЭН у пациентов на гемодиализе.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы: в исследовании принимали участие 80 человек (47 мужчин и 33 женщины), медиана возраста составляла 51,7±11,6 лет. Все пациенты имели ХБП 5Д стадии и получали лечение хроническим гемодиализом, средней длительностью 33,5 (0,5; 236) месяцев. Проводился сбор анамнестических данных, антропометрическое измерение, оценка мышечной силы методом кистевой динамометрии. Уровни MSTN и АКТ определялись в сыворотке крови методом иммуноферментного анализа (ELISA Kit, США). Статистический анализ данных проводился с помощью пакета прикладных программ Microsoft Office (USA) и Statistica-10.0 (StatSoft Inc., USA).</p></sec><sec><title>Результаты</title><p>Результаты: была выявлена зависимость локального увеличения толщины кожных складок при повышении уровня MSTN, а также уменьшение толщины подкожной жировой клетчатки на фоне снижения АКТ (р =0,03). Для оценки степени мышечной деградации был предложен индекс катаболизма мышечной ткани, имеющий статистически подтвержденную связь со степенью БЭН и ее клиническими проявлениями. Анализ влияния маркеров системного воспаления на концентрацию MSTN не дал статистически значимых результатов. Однако в подгруппе с повышенным содержанием АКТ на фоне активации анаболических процессов отмечалось снижение β2- микроглобулина и прирост сывороточного железа (р=0,04). В подгруппе с высоким уровнем MSTN определялись более высокие концентрации паратиреоидного гормона (ПТГ). Обнаружена прямая корреляционная связь между повышением протеинкиназы β и годовой флюктуацией ПТГ (r=0,83, р=0,01).</p></sec><sec><title>Заключение</title><p>Заключение. В проведенном нами исследовании было установлено, что у пациентов с ХБП5Д, получающих терапию хроническим гемодиализом, активность миостатина и протеинкиназы p меняется в сторону превалирования деградации белка над процессами синтеза, что создает предпосылки для развития саркопении. С учетом полученных данных, дальнейшее изучение межмолекулярных взаимодействий данных маркеров в катаболическом каскаде мышечных белков представляет исследовательский интерес.</p></sec></abstract><trans-abstract xml:lang="en"><p>Improving the nephrology service and increasing the availability of hemodialysis create the prerequisites for a deeper analysis of the associated complications and associated diseases. One of the main clinical conditions that worsen the patient’s prognosis is protein-energy deficiency (BPH), which is manifested by loss of muscle mass, strength and performance of skeletal muscles, which also leads to a decrease in quality of life, and often to disability and death.</p><sec><title>The aim</title><p>The aim: assess of the relationship between myostatin and protein kinase β, as markers of the catabolic cascade, with the manifestations of PEW in hemodialysis patients.</p></sec><sec><title>Materials and methods</title><p>Materials and methods: 80 people took part in the study (47 men and 33 women), the median age was 51.7 ± 11.6 years. All patients had CKD 5D stages with chronic hemodialysis treatment for an average duration of 33.5 (0.5; 236) months. All patients were carried out a detailed clinical and anamnestic examination, we estimated the anthropometric measurement, muscular strength were using the hand dynamometry method. The levels of MSTN and AKT were determined in serum by enzyme immunoassay (ELISA Kit, USA). Statistical analysis was carried out using STATISTICA 10.0 (StatSoft Inc., USA) and Microsoft Office Excel 2010 (Microsoft Corp., USA).</p></sec><sec><title>Results</title><p>Results: A dependence of the local increase in skin folds with an increase in the MSTN level, as well as a decrease in the thickness of the subcutaneous fatty tissue with a decrease in AKT (p = 0.03) was detected. We proposed a muscle catabolism index for assessing the degree of muscle degradation. IT had a statistically proven association with degree PEW and clinical manifestations of it. Analysis of the effects of markers of systemic inflammation with MSTN did not give statistically significant results. However, in the subgroup with elevated AKT with the activation of anabolic processes, we observed a decrease in β2-microglobulin and an increase in serum iron (p = 0.04). In the subgroup with a high level of MSTN, higher concentrations of parathyroid hormone (PTH) were determined. We found a direct correlation between the increase in protein kinase β and the annual PTH fluctuation (r = 0.83, p = 0.01).</p></sec><sec><title>Conclusion</title><p>Conclusion. In our study, we were found that in patients with CKD5D receiving therapy with chronic hemodialysis, the activity of myostatin and protein kinase β varies. This leads to an increase in protein degradation over the processes of synthesis, which creates prerequisites for the development of sarcopenia. Taking into account the data obtained, further study of the intermolecular interactions of these markers in the catabolic cascade of muscle proteins is of research interest.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>хроническая болезнь почек</kwd><kwd>белково-энергетическая недостаточность</kwd><kwd>саркопения</kwd><kwd>миостатин</kwd><kwd>протеинкиназа β</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic kidney disease</kwd><kwd>protein-energy deficiency</kwd><kwd>sarcopenia</kwd><kwd>myostatin</kwd><kwd>protein kinase β</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ветчинникова О.Н., Пичугина И.С. Белково-энергетическая недостаточность у пациентов с хронической болезнью почек на диализной терапии, МОНИКИ 1775, Москва. 2015; 3-5</mixed-citation><mixed-citation xml:lang="en">Vetchinnikova O.N., Pichugin I.S. Protein-energy deficiency in patients with chronic kidney disease on dialysis therapy, MONIKI 1775, Moscow. 2015; 3-5. [In Russian].</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Гасанов М.З. Молекулярные аспекты патогенеза саркопении у пациентов с хронической болезнью почек: интегративная роль mTOR. Нефрология. 2018; 22(5): 9-16.</mixed-citation><mixed-citation xml:lang="en">Gasanov M.Z. Molecular aspects of sarcopenia pathogenesis pathogenesis in patients with chronic kidney disease: integrated role of mTOR. Nephrology Journal. 2018; 22(5): 9-16. [In Russian].</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Смирнов А.В., Голубев Р.В., Коростелева Н.Ю. и др. Снижение физической работоспособности у больных, получающих заместительную почечную терапию: фокус на саркопению. Нефрология. 2017; 21(4): 9-29</mixed-citation><mixed-citation xml:lang="en">Smirnov A.V., Golubev R.V., Korosteleva N.Y. et al. Decline of physical performance in patients receiving renal replacement therapy: focus on sarcopenia. Nephrology Journal 2017; 21(4): 9-29. [In Russian].</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bhat M., Kalam R., Qadri S.S., Madabushi S, Ismail A. Vitamin D deficiency-induced muscle wasting occurs through the ubiquitin proteasome pathway and is partially corrected by calcium in male rats. Endocrinology. 2013; 154(11): 4018-4029. DOI: 10.1210/ en.2013-1369</mixed-citation><mixed-citation xml:lang="en">Bhat M., Kalam R., Qadri S.S., Madabushi S, Ismail A. Vitamin D deficiency-induced muscle wasting occurs through the ubiquitin proteasome pathway and is partially corrected by calcium in male rats. Endocrinology. 2013; 154(11): 4018-4029. DOI: 10.1210/ en.2013-1369</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Bing D., Feng Z., Jianghui W. et al. The function of myostatin in the regulation of fat mass in mammals. Nutr Metab. 2017; 14(29): 42. DOI: 10.1186/s12986-017-0179-1.</mixed-citation><mixed-citation xml:lang="en">Bing D., Feng Z., Jianghui W. et al. The function of myostatin in the regulation of fat mass in mammals. Nutr Metab. 2017; 14(29): 42. DOI: 10.1186/s12986-017-0179-1.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Carrero J.J., Johansen K.L., Lindholm B. et. al. Screening for muscle wasting and dysfunction in patients with chronic kidney disease. Kidney Int. 2016; 90(1): 53-66. DOI: 10.1016/j.kint.2016.02.025.</mixed-citation><mixed-citation xml:lang="en">Carrero J.J., Johansen K.L., Lindholm B. et. al. Screening for muscle wasting and dysfunction in patients with chronic kidney disease. Kidney Int. 2016; 90(1): 53-66. DOI: 10.1016/j.kint.2016.02.025.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Domanski M., Ciechanowski K. Sarcopenia: A Major Challenge in Elderly Patients with End-Stage Renal Disease. Journal of Aging Reserch. 2012; article ID: 754739, pages 12. DOI: 10.1155/2012/754739</mixed-citation><mixed-citation xml:lang="en">Domanski M., Ciechanowski K. Sarcopenia: A Major Challenge in Elderly Patients with End-Stage Renal Disease. Journal of Aging Reserch. 2012; article ID: 754739, pages 12. DOI: 10.1155/2012/754739</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ebner N., von Haehling S. Silver linings on the horizon: highlights from the 10th Cachexia Conference. J Cachexia Sarcopenia Muscle. 2018; 9(1):176-182. DOI: 10.1002/jcsm.12290.</mixed-citation><mixed-citation xml:lang="en">Ebner N., von Haehling S. Silver linings on the horizon: highlights from the 10th Cachexia Conference. J Cachexia Sarcopenia Muscle. 2018; 9(1):176-182. DOI: 10.1002/jcsm.12290.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Jiangling D., Yanjun D., Zihong C. et al. The pathway to muscle fibrosis depends on myostatin stimulating the differentiation of fibro/ adipogenic progenitor cells in chronic kidney disease. Kidney Int. 2017; 91(1): 119-128. DOI: 10.1016/j.kint.2016.07.029.</mixed-citation><mixed-citation xml:lang="en">Jiangling D., Yanjun D., Zihong C. et al. The pathway to muscle fibrosis depends on myostatin stimulating the differentiation of fibro/ adipogenic progenitor cells in chronic kidney disease. Kidney Int. 2017; 91(1): 119-128. DOI: 10.1016/j.kint.2016.07.029.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Mak R.H., Ikizler A.T., Kovesdy C.P. et al. Wasting in chronic kidney disease. The Journal of Cachexia, Sarcopenia and Muscle. 2011; 2(1): 9-25. DOI: 10.1007/s13539-011-0019-5</mixed-citation><mixed-citation xml:lang="en">Mak R.H., Ikizler A.T., Kovesdy C.P. et al. Wasting in chronic kidney disease. The Journal of Cachexia, Sarcopenia and Muscle. 2011; 2(1): 9-25. DOI: 10.1007/s13539-011-0019-5</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Sharma M., McFarlane C., Kambadur R. et al. Myostatin: expanding horizons. IUBMB Life. 2015; 67(8): 589-600. DOI:10.1002/iub.1392</mixed-citation><mixed-citation xml:lang="en">Sharma M., McFarlane C., Kambadur R. et al. Myostatin: expanding horizons. IUBMB Life. 2015; 67(8): 589-600. DOI:10.1002/iub.1392</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Wang X.H., Mitch W.E. Mechanisms of muscle wasting in chronic kidney disease. Nat Rev Nephrol. 2014; 10(9): 504-516. DOI: 10.1038/nrneph.2014.112</mixed-citation><mixed-citation xml:lang="en">Wang X.H., Mitch W.E. Mechanisms of muscle wasting in chronic kidney disease. Nat Rev Nephrol. 2014; 10(9): 504-516. DOI: 10.1038/nrneph.2014.112</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Xiaonan H.W., William E.M. Mechanisms of muscle wasting in chronic kidney disease. Nat Rev Nephrol. 2014; 10 (9): 504-516. DOI:10.1038/nrneph.2014.112</mixed-citation><mixed-citation xml:lang="en">Xiaonan H.W., William E.M. Mechanisms of muscle wasting in chronic kidney disease. Nat Rev Nephrol. 2014; 10 (9): 504-516. DOI:10.1038/nrneph.2014.112</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
